Summary The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infections by 2030. However, the HBV prevalence in Western countries, where the historical prevalence is low and highly impacted by immigration trends, remains uncertain making planning difficult. We aimed to develop a more accurate estimate of HBV prevalence and identify key […]
Summary Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease and related mortality globally. However, most of the infected individuals in the United States remain undiagnosed and untreated. There is a need to understand more completely the economic and disease burden impact of removing treatment restrictions and increasing diagnosis and treatment. […]
Resumen La infección crónica por los virus de la hepatitis B y C (VHB y VHC) es una de las principales causas de las enfermedades hepáticas y de la mortalidad relacionada con el hígado en Uzbekistán. Es necesario demostrar la viabilidad de realizar pruebas y tratamientos simplificados a gran escala para implementar un programa nacional de eliminación de la hepatitis viral. Se utilizaron trece policlínicas para realizar pruebas de detección, realizar análisis bioquímicos de seguimiento […]
Resumen En 2019, Estados Unidos no estaba en vías de alcanzar los objetivos de eliminación debido a la creciente incidencia y las barreras de tratamiento. En 2020, la pandemia de COVID-19 interrumpió los servicios de atención de la salud contra el VHC a nivel mundial y en Estados Unidos. A medida que se normalizan los servicios de atención de la salud, existe una necesidad urgente de reevaluar el progreso y evaluar escenarios que restablezcan […]
Summary Background Since the release of the first global hepatitis elimination targets in 2016, and until the COVID-19 pandemic started in early 2020, many countries and territories were making progress toward hepatitis C virus (HCV) elimination. This study aims to evaluate HCV burden in 2020, and forecast HCV burden by 2030 given current trends. Methods This analysis […]
Summary Background Treatment for infection with hepatitis C virus (HCV) during pregnancy has not yet been approved; however, interventions specifically targeting women, especially those of childbearing age (15–49 years), could prevent vertical transmission and community spread. To assess the impact of such interventions, improved prevalence estimates in this group are needed. We aimed to estimate […]
Summary The UNITAID 2013-2016 Strategy includes the treatment of HIV/AIDS and co-infections as one of six strategic objectives. This scoping report focuses on issues, challenges and opportunities related to one of the most important HIV co-infections—Hepatitis C virus (HCV)—and represents UNITAID’s first effort to gather market intelligence on products for the diagnosis and treatment of […]
Spanish 
English 
French 
Russian 
Arabic